API Product   :    Pomalidomide*
CEP   :    -
WCC   :    -
Therapeutic Use    :    Antineoplastics; Immunosuppressants
Originator   :    Celgene Corporation
CAS No.    :    19171-19-8
Trade Name.   :    POMALYST
Molecular Weight   :    273.24 g/mol
Molecular Formula   :    C13H11N3O4
Pomalidomide is used with another medication (such as dexamethasone) to treat a type of cancer in the bone marrow (multiple myeloma). It works by slowing or stopping the growth of cancer cells.
Pomalidomide (INN; marketed as Pomalyst in the U.S. and Imnovid in the EU and Russia) is a derivative of thalidomide marketed by Celgene. It is anti-angiogenic and also acts as an immunomodulator. Pomalidomide was approved in February 2013 by the U.S. Food and Drug Administration (FDA) as a treatment for relapsed and refractory multiple myeloma. It has been approved for use in people who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.